LIB Therapeutics Launches LEROCHOL® (lerodalcibep-liga) in the United States with a Patient-First Approach to Access and Affordability

AI Briefing

• – LIB Therapeutics launches LEROCHOL, a PCSK9 inhibitor for hypercholesterolemia, with a patient-first approach to access and affordability.
• – LEROCHOL is a once-monthly, self-administered treatment for adults with heterozygous familial hypercholesterolemia.
• – The FDA approved LEROCHOL as an adjunct to diet and exercise to reduce LDL-C levels.